Please activate JavaScript!
Please install Adobe Flash Player, click here for download

discovered_02_2013

discovered 02 .13 PORTRAIT WWW.Hzdr.DE // Dresden is enjoying a most excellent reputation as a cancer research hub. A number of awards garnered by scientists from Helmholtz-Zentrum Dresden-Rossendorf and the OncoRay center testify to this. Every year, some 450,000 Germans develop cancer. For progress in the fight against the disease, it is essential for researchers from the most varied of disciplines – biology, chemistry, physics, medicine – to all work together. Here, the smooth transfer of insights gleaned in basic research into the clinical setting where it can ultimately benefit patients (as well as from the clinical setting into the research lab) is key. This is precisely the reason why as recently as September 2013, ECCO, the European CanCer Organisation, presented its Clinical Research Award to Michael Baumann, Director of the HZDR’s Institute of Radiooncology. With this award, the multidisciplinary governing body, which is comprised of oncological societies, cancer researchers, and patient organizations, recognizes Baumann’s outstanding contributions in the area of integrating scientific findings into the clinical setting. "In my work, translational thinking has always been integral, in other words, the idea of taking insights that hold potential for cancer therapy from the lab through the clinical trial stage and into the clinical setting where they can benefit patients," stresses Baumann, who is also the Director of OncoRay, Dresden’s National Center for Radiation Research in Oncology, which is run jointly by HZDR, the University Hospital Carl Gustav Carus, and the TU Dresden. _TEXT . Simon Schmitt From early detection to the fight against diseased cells HONOREE: Michael Baumann at the OncoRay Center Dresden’s gantry. Right at the heart of this huge bending magnet, the first cancer patients will be treated with protons beginning in the fall of 2014. Photo: UKD/Christoph Reichelt

Seitenübersicht